Bristol-myers Squibb Compnay

Exelixis Patent Company LLC

Britsol-myers Squibb Company

Ellen K Kick

Meriah Neissel Valente

Raju Mohan

R Michael Lawrence

Richard Martin

James A Johnson

Nicholas Ronald Wurtz

Joanne M Smallheer

Pravin Sudhakar Shirude

Scott A Shaw

Amit Kumar Chattopadhyay

Andrew K Dilger

Sutjano Jusuf

Balaji Seshadri

Vishweshwaraiah Baligar

Wu Yang

Carol Hui Hu

Brett Bradley Busch

Kumar Balashanmuga Pabbisetty

Oz Scott Halpern

Benjamin P Vokits

Mandar Shrikrishna Bodas

Andrew Quoc Viet

Brian E Fink

Raj N Misra

Yufeng Wang

Karen Anita Rossi

Gregory D Vite

Venkataiah Bollu

Satheesh Kesavan Nair

Charles G Clark

Jayakumar Sankara Warrier

Zulan Pi

Chenkou Wei

Hannguang J Chao

William C Stevens, Jr

Chandrasekhar Reddy Rachamreddy

Sharanabasappa Patil

Claudia Averbuj

Huji Tuerdi

Haiying Zhang

Prasanna Savanor Maddu Rao

Victor R Guarino

Ching-Chiang Su

Michael J Hageman

William C Stevens

Jeevanprakash Shetty

Alla Venu

The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Phenylpyrrolidinone formyl peptide 2 receptor agonists

The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases. 

Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists

The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. 

Piperidinone formyl peptide 2 receptor agonists

The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. 

Triazolopyridine inhibitors of myeloperoxidase and/or EPX

The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. 

Macrocyclic inhibitors of myeloperoxidase

The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

Triazolopyridine inhibitors of myeloperoxidase

The present invention provides compounds of Formula (I): wherein A, Y and Rare each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments. 

The present invention provides compounds of Formula (I): wherein A and Rare each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments. 

Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXR), compositions comprising any of such novel compounds, methods of using these compounds or compositions as medicaments for prevention or treatment of diseases or disorders related to liver X receptor (LXR), as well as methods of preparing these LXR modulators and using them in the manufacture of medicaments. 

LXR modulators

The present invention provides compounds of Formula I and Formula II: or pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXRs), and compositions comprising any of such novel compounds and methods of use thereof. These compounds are useful as medicaments for treatment and/or prophylaxis for diseases or conditions related to activity of LXRs. 

Imidazole prodrugs, pharmaceutically acceptable salts, or isomers thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

Imidazole prodrug LXR modulators

Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

A compound of formula I wherein X, R, R, R, R, R, R, Rand Rare defined herein.

Tetrahydroisoquinoline LXR Modulators

Growing community of inventors

Pennington, NJ, United States of America

Ellen K Kick